NYSEMKT: ERNAEterna Therapeutics Inc Stock
$3.22-0.27 (-7.74%)
Updated Mar 20, 2023
ERNA Price
$3.22
Fair Value Price
N/A
Market Cap
$16.51M
52 Week Low
$2.74
52 Week High
$45.76
P/E
-0.4x
P/B
1.36x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$24.58M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.84
Operating Cash Flow
-$21M
Beta
0.85
Next Earnings
Apr 14, 2023
Ex-Dividend
N/A
Next Dividend
N/A
ERNA Overview
NTN Buzztime, Inc. engages in the provision of entertainment and innovative technology services. The company is headquartered in Carlsbad, California and currently employs 94 full-time employees. The firm provides an entertainment and marketing services platform for hospitality venues that offers games, events, and entertainment experiences to their customers. Its customers offer guests trivia, card, sports and arcade games, nationwide competitions, and self-service dining features, including dynamic menus, touchscreen ordering and secure payment by licensing the Company's customizable solution. Its platform creates connections among the players and venues. Its network subscriber venues are related to national and regional restaurant brands, including Buffalo Wild Wings, Old Chicago, Beef O'Brady's, Aroogas, Buffalo Wings & Rings, Native New Yorker and Boston Pizza. Its entertainment system enables players to interact at the venue, and it also enables competition between venues, referred to as multiplayer gaming.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ERNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ERNA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ERNA is good value based on its book value relative to its share price (1.36x), compared to the US Biotechnology industry average (4.81x)
P/B vs Industry Valuation
ERNA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ERNA due diligence checks available for Premium users.
Be the first to know about important ERNA news, forecast changes, insider trades & much more!
ERNA News
Valuation
ERNA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.4x
Industry
16.1x
Market
22.37x
ERNA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.36x
Industry
4.81x
ERNA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ERNA's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.5M
Profit Margin
0%
ERNA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$22.3M
Liabilities
$10.2M
Debt to equity
0.84
ERNA's short-term assets ($13.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ERNA's short-term assets ($13.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ERNA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ERNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.4M
Investing
$129.0k
Financing
$7.6M
ERNA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ERNA vs Biotech Stocks
Eterna Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.